Venlo, The Netherlands – Qiagen said Wednesday it introduces artificial intelligence (AI)-driven biomedical knowledge base to speed up data-driven drug discovery by identifying relationships between genes, diseases, and drugs, aiding in therapeutic advancements.
The new tool complements existing human-curated knowledge bases and offers structured data for efficient hypothesis testing.
Built upon an extensive dataset of biomedical literature and other scientific resources, QIAGEN Biomedical KB-AI stands out for its use of generative AI to identify and extract causal relationships across a vast array of biological entities, including genes, diseases, and drugs.
The knowledge base has successfully generated over 600 million biomedical relationships, surpassing its counterpart, QIAGEN Biomedical KB-HD, by a significant margin.